Longevity Needs a Scientific Sanity Check: Dr Herna de Wit on Evidence, IP and South Africa’s Role in the Future of Healthspan

This week on Beyond Longevity, I am joined by Dr Herna de Wit, CEO and Founder of Omnisci Consulting, with a PhD in Biochemistry and an LLB in Law.

Dr Herna brings a very unusual and valuable combination to the longevity conversation: deep scientific training, legal expertise and hands-on experience advising companies in the health, biotech and longevity space.

Longevity is full of exciting science, but it is also a field where marketing can move faster than evidence. In this episode, we ask a simple but important question: how do we separate what is genuinely credible from what merely sounds convincing?

Dr Herna shares her five-point “scientific sanity check” for evaluating longevity products, supplements and protocols. We discuss why human RCT data matters more than animal or cell studies, why dosage and bioavailability are often overlooked, what biological age clocks can and cannot tell us, and why safety, third-party testing, and regulatory discipline are essential in a fast-moving market.

We also look at longevity from the perspective of investors and company builders. What are the red flags? What makes a claim scientifically weak? And why does defensible intellectual property matter far beyond simply having a patent?

Dr Herna explains how companies can think more intelligently about protectability, including through delivery systems, synergistic formulations, data, know-how and clearer scientific positioning.

The conversation then turns to South Africa, a market that many listeners may not immediately associate with longevity, but one that raises fascinating questions. We discuss medical tourism, scientific talent, regulatory realities, affordability and whether South Africa could carve out a distinctive role in the global healthspan conversation.

Finally, we speak about one of the most important tensions in longevity: if the science advances, who actually gets access? Is longevity already becoming another layer of privilege, or can the field develop in a way that is more credible, more inclusive and more useful?

This is a conversation about evidence, accountability and the future of a field that urgently needs both excitement and discipline.

Links:

https://www.linkedin.com/in/herna-de-wit-phd-llb/

https://linktr.ee/drherna.omnisci

00:00 Show Intro and Guest

02:41 Dr Herna’s Unusual Path

04:29 What She Does Today

06:13 Five Point Science Audit

11:17 Investor Red Flags

15:31 IP Beyond Patents

20:12 Open Science vs Profit

24:35 Founder IP Strategy

32:54 Global Longevity Hotspots

33:42 South Africa Opportunity

36:33 Access and Inequality

43:12 Regulation and Innovation

46:20 How to Work With Dr Herna

50:02 Rapid Fire Questions

52:20 Final Takeaways Outro